LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mesa Biotech Showcases PCR Testing Platform at Clinical Expo

By LabMedica International staff writers
Posted on 02 Aug 2018
Print article
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Mesa Biotech Inc. (San Diego, CA, USA), a privately-held, molecular diagnostic company, showcased its affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis at the 70th Annual American Association of Clinical Chemistry Scientific Meeting & Clinical Lab Expo (AACC). AACC 2018 was held on July 29 – August 2, 2018, in Chicago, Illinois, USA.

Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the POC. At AACC 2018, Mesa Biotech showcased its novel Accula System – a palm-sized, reusable dock with disposable test cassettes that offers the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays, while providing the superior sensitivity, specificity and information content of laboratory-based PCR testing. Test results are available in approximately 30 minutes to guide same-day treatment decisions. The handheld platform delivers flexibility in POC, ranging from the physician's office and walk-in clinics to emergency rooms. Accula Flu A/Flu B, the first commercialized test on the platform, is indicated for use with nasal swab collection that is less invasive than nasopharyngeal swabs and allows for a more comfortable specimen collection experience for the patient.

"We are excited to be a part of this leading industry conference and showcase our recently launched testing platform to the more than 20,000 attendees," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "AACC is an important opportunity for us to connect with global leaders, highlight new assays under development and identify additional partnership opportunities."

Related Links:
Mesa Biotech

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more